Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update

Author's Avatar
May 09, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2023 and provided a business update.